000 01283 a2200397 4500
005 20250514020204.0
264 0 _c20011228
008 200112s 0 0 eng d
022 _a0098-7484
040 _aNLM
_beng
_cNLM
100 1 _aSchwetz, B A
245 0 0 _aFrom the Food and Drug Administration.
_h[electronic resource]
260 _bJAMA
_cDec 2001
300 _a2660 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdenine
_xanalogs & derivatives
650 0 4 _aAdministration, Oral
650 0 4 _aAnti-HIV Agents
_xtherapeutic use
650 0 4 _aCathartics
_xadministration & dosage
650 0 4 _aDefibrillators, Implantable
650 0 4 _aHIV Infections
_xdrug therapy
650 0 4 _aHIV-1
650 0 4 _aHumans
650 0 4 _aMonitoring, Ambulatory
650 0 4 _aOrganophosphonates
650 0 4 _aOrganophosphorus Compounds
_xtherapeutic use
650 0 4 _aPacemaker, Artificial
650 0 4 _aPharmaceutical Solutions
650 0 4 _aPhosphates
_xadministration & dosage
650 0 4 _aTenofovir
650 0 4 _aUnited States
650 0 4 _aUnited States Food and Drug Administration
650 0 4 _aViral Load
650 0 4 _aWater-Electrolyte Imbalance
_xchemically induced
773 0 _tJAMA
_gvol. 286
_gno. 21
_gp. 2660
999 _c11644335
_d11644335